

# VAP-1 (TK8-14): sc-33670

## BACKGROUND

Lymphocyte binding to vascular endothelium is a prerequisite for the movement of immune cells from the blood into lymphoid tissues and into sites of inflammation. Under inflammatory conditions, cell surface expression of VAP-1 (vascular adhesion protein-1) which is an endothelial sialoglycoprotein, is induced. VAP-1 is a type II transmembrane protein with a single transmembrane domain and N- and O-glycosylation sites in the extracellular domain. *In vivo*, VAP-1 exists predominantly as a homodimer and functions both as an enzyme (monoamine oxidase) and an adhesion molecule for lymphocytes. With the appropriate glycosylation and in the correct inflammatory setting, expression of VAP-1 on the luminal endothelial cell surface allows it to mediate lymphocyte adhesion and to function as an adhesion receptor involved in lymphocyte recirculation. VAP-1 is also expressed in all types of smooth muscle cells, except in cardiac and skeletal muscle cells. VAP-1 localized on smooth muscle cells does not support binding of lymphocytes, but it deaminates exogenous and endogenous primary amines. Soluble VAP-1 is found in circulation and its level is increased in patients who have inflammatory liver diseases.

## REFERENCES

- Salminen, T.A., et al. 1998. Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase. *Protein Eng.* 11: 1195-1204.
- Smith, D.J., et al. 1998. Cloning of vascular adhesion protein-1 reveals a novel multifunctional adhesion molecule. *J. Exp. Med.* 188: 17-27.
- Kurkijarvi, R., et al. 1998. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. *J. Immunol.* 161: 1549-1557.
- Slami, M., et al. 2000. Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear. *Circ. Res.* 86: 1245-1251.

## CHROMOSOMAL LOCATION

Genetic locus: AOC3 (human) mapping to 17q21.31.

## SOURCE

VAP-1 (TK8-14) is a mouse monoclonal antibody raised against affinity purified VAP-1 from tonsil stroma of human origin.

## PRODUCT

Each vial contains 200 µg IgG<sub>2a</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

VAP-1 (TK8-14) is available conjugated to phycoerythrin (sc-33670 PE), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## APPLICATIONS

VAP-1 (TK8-14) is recommended for detection of VAP-1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10<sup>6</sup> cells).

Suitable for use as control antibody for VAP-1 siRNA (h): sc-43197, VAP-1 shRNA Plasmid (h): sc-43197-SH and VAP-1 shRNA (h) Lentiviral Particles: sc-43197-V.

Molecular Weight (predicted) of VAP-1: 85 kDa.


Molecular Weight (observed) of VAP-1: 110 kDa.

Positive Controls: human lung extract: sc-363767.

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## DATA



VAP-1 (TK8-14): sc-33670. Western blot analysis of VAP-1 expression in human lung tissue extract.

## SELECT PRODUCT CITATIONS

- Noonan, T., et al. 2013. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. *Am. J. Clin. Exp. Immunol.* 2: 172-185.
- Esser, C., et al. 2014. Evidence of promiscuous endothelial binding by *Plasmodium falciparum*-infected erythrocytes. *Cell. Microbiol.* 16: 701-708.
- Vilhav, C., et al. 2018. Fractional uptake of circulating tumor cells into liver-lung compartments during curative resection of periampullary cancer. *Oncol. Lett.* 16: 6331-6338.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.